TrialThe Journal of clinical investigation2019

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.

Richard Furie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.